Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.

Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W Jr, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H.

Int J Cancer. 2017 Dec 1;141(11):2348-2358. doi: 10.1002/ijc.30929. Epub 2017 Aug 26.

PMID:
28801914
2.

Targeting Autophagy for Oncolytic Immunotherapy.

Hu L, Jiang K, Ding C, Meng S.

Biomedicines. 2017 Jan 11;5(1). pii: E5. doi: 10.3390/biomedicines5010005. Review.

3.

Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.

Jaime-Ramirez AC, Dmitrieva N, Yoo JY, Banasavadi-Siddegowda Y, Zhang J, Relation T, Bolyard C, Wojton J, Kaur B.

J Gene Med. 2017 Mar;19(3). doi: 10.1002/jgm.2942.

4.

Oncolytic virotherapy using herpes simplex virus: how far have we come?

Sokolowski NA, Rizos H, Diefenbach RJ.

Oncolytic Virother. 2015 Nov 25;4:207-19. doi: 10.2147/OV.S66086. eCollection 2015. Review.

5.

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.

Braidwood L, Graham SV, Graham A, Conner J.

Oncolytic Virother. 2013 Dec 4;2:57-74. doi: 10.2147/OV.S52601. eCollection 2013. Review.

6.

Oncolytic virus as a cancer stem cell killer: progress and challenges.

Ding J.

Stem Cell Investig. 2014 Dec 28;1:22. doi: 10.3978/j.issn.2306-9759.2014.12.02. eCollection 2014. Review.

7.

Targeting cancer stem cells with oncolytic virus.

Tong Y, Qian W.

Stem Cell Investig. 2014 Nov 28;1:20. doi: 10.3978/j.issn.2306-9759.2014.11.01. eCollection 2014. Review.

8.

A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Nigim F, Esaki S, Hood M, Lelic N, James MF, Ramesh V, Stemmer-Rachamimov A, Cahill DP, Brastianos PK, Rabkin SD, Martuza RL, Wakimoto H.

Neuro Oncol. 2016 Sep;18(9):1278-87. doi: 10.1093/neuonc/now031. Epub 2016 Mar 6.

9.

EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

Saha D, Ahmed SS, Rabkin SD.

Drugs Future. 2015;40(11):739-749.

10.

Designing Herpes Viruses as Oncolytics.

Peters C, Rabkin SD.

Mol Ther Oncolytics. 2015;2. pii: 15010. Epub 2015 Jul 22.

11.

Harnessing the apoptotic programs in cancer stem-like cells.

Wang YH, Scadden DT.

EMBO Rep. 2015 Sep;16(9):1084-98. doi: 10.15252/embr.201439675. Epub 2015 Aug 7. Review.

12.

Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.

Spencer DA, Young JS, Kanojia D, Kim JW, Polster SP, Murphy JP, Lesniak MS.

Ther Deliv. 2015;6(4):453-68. doi: 10.4155/tde.14.123. Review.

13.

In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.

McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA.

Neuro Oncol. 2015 Aug;17(8):1086-94. doi: 10.1093/neuonc/nou359. Epub 2015 Jan 20.

14.

Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.

Bolyard C, Yoo JY, Wang PY, Saini U, Rath KS, Cripe TP, Zhang J, Selvendiran K, Kaur B.

Clin Cancer Res. 2014 Dec 15;20(24):6479-94. doi: 10.1158/1078-0432.CCR-14-0463. Epub 2014 Oct 7.

15.

Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.

Forbes NE, Krishnan R, Diallo JS.

Front Oncol. 2014 Jul 23;4:191. doi: 10.3389/fonc.2014.00191. eCollection 2014. Review.

16.

Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land.

Guo ZS, Bartlett DL.

Cancer Gene Ther. 2014 Jul;21(7):261-3. doi: 10.1038/cgt.2014.31. No abstract available.

17.

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.

Ning J, Wakimoto H.

Front Microbiol. 2014 Jun 20;5:303. doi: 10.3389/fmicb.2014.00303. eCollection 2014. Review.

18.

Oncolytic viral therapy: targeting cancer stem cells.

Smith TT, Roth JC, Friedman GK, Gillespie GY.

Oncolytic Virother. 2014 Feb;2014(3):21-33.

19.

Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ΔPK oncolytic activity in melanoma.

Colunga A, Bollino D, Schech A, Aurelian L.

Gene Ther. 2014 Apr;21(4):371-8. doi: 10.1038/gt.2014.6. Epub 2014 Feb 20.

20.

Glioma virus therapies between bench and bedside.

Kaufmann JK, Chiocca EA.

Neuro Oncol. 2014 Mar;16(3):334-51. doi: 10.1093/neuonc/not310. Epub 2014 Jan 26. Review.

Supplemental Content

Support Center